Current therapeutic approach of chronic kidney disease‐mineral and bone disorder

• Published in: Therapeutic apheresis and dialysis 2024-10, Vol.28 (5), p.671-689
• Main Authors: Zaimi, Maria, Grapsa, Eirini
• Format: Article
• Language: English
• Subjects: anti‐osteoporotic agents; chronic kidney disease‐mineral and bone disorder (CKD‐MBD); hormonal abnormalities; management of electrolytic abnormalities; renal osteodystrophy; vitamin D administration
• ISSN: 1744-9979; 1744-9987; 1744-9987
• DOI: 10.1111/1744-9987.14177

Chronic kidney disease (CKD) has emerged as one of the leading noncommunicable diseases affecting >10% of the population worldwide. Bone and mineral disorders are a common complication among patients with CKD resulting in a poor life quality, high fracture risk, increased morbidity and cardiovascular mortality. According to Kidney Disease: Improving Global Outcomes, renal osteodystrophy refers to changes in bone morphology found in bone biopsy, whereas CKD‐mineral and bone disorder (CKD‐MBD) defines a complex of disturbances including biochemical and hormonal alterations, disorders of bone and mineral metabolism and extraskeletal calcification. As a result, the management of CKD‐MBD should focus on the aforementioned parameters, including the treatment of hyperphosphatemia, hypocalcemia, abnormal PTH and vitamin D levels. Regarding the bone fragility fractures, osteoporosis and renal osteodystrophy, which constitute the bone component of CKD‐MBD, anti‐osteoporotic agents constitute the mainstay of treatment. However, a thorough elucidation of the CKD‐MBD pathogenesis is crucial for the ideal personalized treatment approach. In this paper, we review the pathology and management of CKD‐MBD based on the current literature with special attention to recent advances.